June 19, 2015
A New Jersey federal judge denied Jazz Pharmaceuticals Inc.'s appeal of an order allowing Roxane Laboratories Inc. to amend its invalidity and noninfringement arguments in a suit over a planned generic of Jazz's narcolepsy drug Xyrem, saying Friday the amendments are timely.
June 25, 2014
Amneal Pharmaceuticals LLC and others asked the Patent Trial and Appeal Board on Tuesday to invalidate a patent for distribution of Jazz Pharmaceuticals Inc.'s narcolepsy drug Xyrem as an abstract idea, the first time the America Invents Act's business method review program has been used in a drug case.